Otsuka inks deal for rights to migraine drug candidate fremanezumab
Japan’s Otsuka Pharmaceutical (TYO: 4578) has signed a deal to acquire rights to the investigational drug candidate fremanezumab (TEV-48125).
The drug is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine, under development by Israel’s Teva Pharmaceutical Industries (NYSE: TEVA). Through the agreement, Otsuka secures exclusive rights in Japan to fremanezumab, which Teva is globally developing in other countries.
The annual prevalence of migraine in Japan is 8.4% of adults and around 8.4 million patients suffer from the condition. The highest prevalence rate is among young women, with about 20% of cases reported among women in their 30s. Acute as well as preventive treatments exist for migraine, but there is an unmet need for targeted, preventive therapies, noted Teva.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze